Biosimilars

What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
 

What can we help you find?
[[thumbnail_alt_text]]
Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.
[[thumbnail_alt_text]]
Cancer care providers have increasingly been using biosimilars on a case-by-case basis with patients.
 
[[thumbnail_alt_text]]
Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer
[[thumbnail_alt_text]]
Mylan plans to launch adalimumab-fkjp in the United States in July 2023.
[[thumbnail_alt_text]]
FDA officials based their approval on the review of data and evidence that demonstrated a close similarity between pegfilgrastim-apgf and its reference product.
[[thumbnail_alt_text]]
Considerations of biosimilars as a valuable asset to the health care system, the impact of the competition biosimilars have on biologics regarding price and rebates, and final thoughts.
[[thumbnail_alt_text]]
A discussion on the pricing of biosimilars and factors that limit the cost-savings potential.
[[thumbnail_alt_text]]
Common myths and misconceptions for biosimilars are explored.
[[thumbnail_alt_text]]
The panel discusses patient awareness of biosimilar products and whether they provide supplemental patient education through patient information sheets.
[[thumbnail_alt_text]]
The scope of the clinical pharmacist is discussed in switching a patient over to a preferred biosimilar along with the role of specialty pharmacy.
[[thumbnail_alt_text]]
A discussion on limiting the number of biosimilars available for the same product at an institution regarding inventory, fridge space, and safety.
[[thumbnail_alt_text]]
The panel explores the appropriateness of switching from a biologic to a biosimilar through consideration of factors such as the curative vs noncurative setting, the EMR system, and patient education.